Advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.
This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.
This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.
This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.
Here we draw attention to promising findings for CAR T lupus treatment. The foundations of CAR T, as well as applications for B cell cancers and multiple myeloma, can be found in earlier works in the series.
This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.”
The first installment lays the foundation for understanding how CAR T works. This second piece delves into the use of CAR T to treat B cell cancers.
This first installment will lay the foundation for understanding how CAR T works. Future installments will focus on CAR T applications and recent innovations which further the field.
